As the global markets brace for another tumultuous week, the interplay between geopolitical tensions and sector-specific dynamics is shaping the investment landscape. The escalation in US-Iran tensions has injected a fresh dose of volatility, with investors closely monitoring the potential for conflict to disrupt global oil supplies and exacerbate inflationary pressures. This geopolitical backdrop is particularly concerning as it coincides with significant inflation data releases and Federal Reserve commentary, which are expected to provide further insights into the central bank's monetary policy trajectory. In the corporate sphere, the airline sector is navigating a challenging environment, with fluctuating fuel prices and uncertain demand patterns adding to operational complexities. Meanwhile, the semiconductor industry is experiencing a notable rotation, driven by recalibrations in AI infrastructure investments. Companies like Nvidia, CoreWeave, and Cerebras Systems are under the microscope as investors assess their resilience amidst a broader market pullback. The recent scrutiny of Nvidia's CEO over alleged espionage ties has further rattled investor confidence, underscoring the fragility of the AI trade. Energy companies, on the other hand, are grappling with the dual pressures of geopolitical risks and shifting market dynamics. The potential for renewed sanctions on Iran could tighten oil markets, providing a temporary reprieve for energy stocks. However, the long-term outlook remains uncertain as the transition to renewable energy sources continues to gain momentum. Corporate earnings reports are also in focus, with companies like Trump Media & Technology Group and Paramount Skydance set to release results. These reports will offer a glimpse into how businesses are faring in the current economic climate, with particular attention on their ability to manage costs and sustain growth. As the market digests these multifaceted developments, the overarching narrative is one of caution and recalibration. Investors are balancing the prospects of a potential economic slowdown against the backdrop of persistent inflationary pressures and geopolitical uncertainties. The coming days will be critical in shaping market sentiment, with key data releases and corporate earnings poised to provide further clarity on the path ahead. In this environment, agility and a keen understanding of both macroeconomic trends and micro-level corporate performance will be essential for navigating the market's complexities.
Companies Reporting Earnings Today
| Symbol | Price | Change | MarketCap |
|---|---|---|---|
| CEG | 249.9500 | 4.30% | 88559129381 |
| KKR | 96.4800 | -1.85% | 86603921280 |
| B | 40.5600 | 0.55% | 66757072035 |
| OXY-WT | 34.4600 | 0.50% | 56618691501 |
| OXY | 56.3800 | 0.04% | 56359534060 |
| FERG | 233.7000 | -0.83% | 45209899963 |
| TTWO | 214.8700 | 0.71% | 40176392600 |
| IX | 34.8500 | -2.76% | 38690927162 |
| RKLB | 53.0700 | 15.39% | 31760258349 |
| ROIV | 38.8800 | 6.17% | 28083918823 |
| JBS | 12.4800 | -2.50% | 27681968995 |
| BAP | 347.9300 | -0.02% | 27632362964 |
| CIB | 92.3700 | 0.16% | 21814605757 |
| NRG | 88.2900 | 9.61% | 18559483544 |
| KSPI | 91.6800 | 0.11% | 17421699747 |
| RBA | 93.5200 | -1.33% | 17319904000 |
| SGI | 64.1700 | -5.45% | 14774436630 |
| CNH | 11.5600 | 2.76% | 14308158800 |
| EQX | 11.5200 | 2.08% | 13449137149 |
| ASTS | 32.3300 | 7.05% | 13200746940 |
| FRHC | 178.8500 | 0.95% | 11408424064 |
| AMG | 362.6300 | 3.45% | 9377587504 |
| MGRD | 13.7800 | 0.58% | 9377587496 |
| MGRB | 15.3500 | -0.20% | 9377587493 |
| MGRE | 21.0500 | -0.28% | 9377587487 |
| TGTX | 59.8250 | 3.18% | 9158225174 |
| IBRX | 8.6350 | 7.80% | 9151686217 |
| LINE | 39.1300 | -1.01% | 8908897902 |
| SKYD | 8.0100 | -1.72% | 8755090200 |
| TIMB | 18.1300 | -0.49% | 8618188162 |
| ONTO | 173.2800 | 11.08% | 8503585520 |
| APGE | 135.0700 | 0.00% | 8401501632 |
| ZETA | 31.0300 | 5.29% | 7758047804 |
| PRAX | 277.6200 | 5.72% | 7751147069 |
| SANM | 134.6800 | 3.42% | 7218497832 |
| CWEN | 34.1000 | -0.53% | 6999872180 |
| QLYS | 190.4100 | -4.62% | 6587234140 |
| IONS | 39.4200 | 1.60% | 6550973280 |
| HRB | 52.6900 | -4.22% | 6454159542 |
| IMVT | 30.5300 | 7.54% | 6306053381 |
| CWST | 98.2100 | -1.85% | 6153033278 |
| TTD | 12.9300 | 0.94% | 6113241083 |
| HIMS | 26.0000 | 8.06% | 5848330540 |
| NXE | 8.2500 | 4.04% | 5531674500 |
| COGT | 31.6450 | 6.98% | 5491197897 |
| MGR | 18.6000 | 0.16% | 5482234792 |
| IFS | 46.5900 | -1.52% | 5143429076 |
| NOVT | 135.1500 | 2.53% | 5111071616 |
| GBTG | 9.5000 | -0.05% | 4962547709 |
| TEO | 9.9700 | -0.99% | 4865769149 |
| AAON | 57.1900 | 5.09% | 4715521384 |
| DFTX | 33.2700 | 9.58% | 4470388094 |
| KGS | 41.6700 | 7.04% | 4213004972 |
| TKC | 4.5700 | -0.65% | 3978536991 |
| LIF | 47.3700 | 1.07% | 3859725080 |
| ABCL | 11.8800 | 6.74% | 3849678360 |
| XENE | 39.1700 | 3.95% | 3793238468 |
| EQPT | 14.6800 | 7.39% | 3719559166 |
| MNDY | 87.9300 | -6.30% | 3717163284 |
| NHI | 71.2400 | -0.47% | 3498624896 |
| TDW | 70.0600 | 1.42% | 3485919372 |
| ACHR | 4.4400 | 14.73% | 3418918992 |
| DHT | 20.6800 | 0.98% | 3334351650 |
| SGRY | 23.2000 | 0.13% | 2989900000 |
| VIA | 37.7200 | -0.03% | 2921402231 |
| DAC | 148.1100 | -0.54% | 2696135196 |
| SB-PC | 26.1500 | 2.47% | 2675668000 |
| FRVO | 9.0250 | 15.85% | 2659142606 |
| SB-PD | 25.4650 | 0.26% | 2605578800 |
| MARA | 6.3500 | 8.09% | 2452998650 |
| CSQR | 14.3400 | 4.52% | 2389531331 |
| EXK | 7.8400 | 3.23% | 2321768960 |
| ALM | 8.1200 | 2.14% | 2303985040 |
| SEPN | 48.8500 | 3.17% | 2280168861 |
| NOVTU | 57.4200 | 2.43% | 2171498076 |
| WTTR | 16.1800 | 4.79% | 2169612168 |
| ZYME | 29.6300 | 3.11% | 2130394600 |
| TRVI | 14.3300 | 11.87% | 2041678802 |
| PLUG | 1.4500 | 7.41% | 2025933153 |
| GSHD | 55.5500 | -2.34% | 2019792501 |
| NESR | 19.9600 | 3.96% | 2013001010 |
| KMPR | 33.3900 | -5.49% | 1965810606 |
| KMPB | 24.9800 | 0.12% | 1965810592 |
| WGS | 62.3700 | -3.09% | 1860029325 |
| GSL-PB | 26.3650 | -0.17% | 1493848651 |
| OCUL | 6.5950 | 2.57% | 1448366649 |
| QUBT | 6.3300 | 12.43% | 1432775630 |
| GSL | 39.0300 | 0.93% | 1406461662 |
| BW-PA | 17.3900 | 1.10% | 1370367110 |
| TPB | 65.8800 | -2.36% | 1320821532 |
| WBTN | 9.6700 | 2.22% | 1312326047 |
| DOLE | 13.8800 | 0.29% | 1311088241 |
| UNIT | 5.2200 | -2.70% | 1267025205 |
| APPS | 10.3800 | 7.34% | 1263472855 |
| GDRX | 3.5100 | 0.57% | 1197420336 |
| AMRC | 21.6100 | 12.85% | 1146760820 |
| SECZ | 6.9600 | -5.05% | 1136329168 |
| TH | 11.3600 | 9.02% | 1131721824 |
| DJT | 3.9900 | -0.75% | 1108985707 |
| USAR | 8.2250 | 10.85% | 1090952164 |
| LCID | 3.2900 | 10.40% | 1045819229 |
| HROW | 26.8900 | 3.26% | 1008048287 |
| MUX | 15.4800 | 4.10% | 924776547 |
| HPK | 7.1400 | 0.00% | 902873021 |
| DSP | 12.8450 | 1.54% | 854177317 |
| VRTS | 127.3500 | 1.99% | 843399572 |
| PAYS | 14.6900 | 2.58% | 829429072 |
| PUBM | 17.8100 | 6.14% | 811246658 |
| SB | 7.1100 | 0.71% | 809352630 |
| GCMG | 12.6600 | 1.04% | 773858566 |
| CNNE | 17.6900 | -0.79% | 767290076 |
| CEVA | 27.1000 | 10.34% | 762975351 |
| EDN | 14.0800 | -0.49% | 738107927 |
| BCSF | 11.1400 | -0.27% | 722635168 |
| MLAB | 128.2500 | 7.50% | 717670199 |
| GDOT | 12.2400 | -1.61% | 697498591 |
| ANNX | 4.2000 | 4.87% | 688138660 |
| APEI | 37.2800 | -2.46% | 682281523 |
| AURA | 6.5600 | 3.47% | 680303547 |
| AVBP | 13.6400 | 11.53% | 672557410 |
| GMRS | 12.4400 | -0.56% | 672030072 |
| TRON | 1.4100 | 4.44% | 668878691 |
| RXT | 2.5300 | 6.30% | 644828311 |
| OLMA | 7.3300 | 8.43% | 641357408 |
| GRPN | 15.4900 | -0.58% | 629905435 |
| GAINZ | 24.0900 | 0.00% | 594940660 |
| GAIN | 14.8600 | -0.54% | 591754920 |
| GAINI | 25.2290 | -0.00% | 591754899 |
| EVGO | 1.8300 | 4.57% | 574362638 |
| BCAX | 8.6500 | 5.62% | 572395879 |
| QMCO | 14.4700 | 5.70% | 570262714 |
| FWRD | 16.6400 | -1.71% | 562113544 |
| LINC | 17.6600 | 0.63% | 560201319 |
| KKRT | 22.5600 | -0.75% | 532416000 |
| BTGO | 4.8600 | 2.10% | 528234566 |
| DCTH | 14.9300 | 3.04% | 518053009 |
| ETD | 20.0700 | -3.04% | 505852629 |
| HIVE | 1.7800 | 9.20% | 488213662 |
| BW | 3.2500 | 4.84% | 484136250 |
| HNRG | 10.1000 | 7.91% | 476147906 |
| SENS | 8.5900 | 7.51% | 454188115 |
| CWCO | 27.2200 | 2.56% | 435870185 |
| RLGT | 8.8900 | -1.55% | 417648644 |
| KMDA | 7.2300 | 5.24% | 417129789 |
| SOHU | 13.8300 | 1.54% | 415804468 |
| ASMB | 20.4200 | 2.10% | 415763370 |
| THM | 1.5400 | 27.27% | 402920980 |
| NGNE | 25.3100 | -1.33% | 399956871 |
| EDIT | 2.5700 | 0.78% | 394700600 |
| ALTI | 2.3400 | -1.68% | 390431373 |
| RPAY | 4.4000 | -3.51% | 388011325 |
| MNTK | 2.7200 | 12.86% | 387167898 |
| CTEV | 22.7100 | 12.31% | 384877725 |
| PROK | 1.1400 | 7.04% | 383329421 |
| QVCG | 7.5400 | -2.20% | 376999223 |
| SMC | 27.1300 | 1.27% | 373949556 |
| SOC | 1.9300 | 6.04% | 370308274 |
| AIOT | 2.6900 | 3.86% | 361067719 |
| SLI | 1.4600 | 6.57% | 360304640 |
| TLS | 4.8200 | 0.84% | 360231376 |
| NGS | 27.6200 | 3.52% | 356250632 |
| BDCI | 10.1800 | 0.00% | 353721050 |
| VFF | 2.8800 | 3.23% | 352184535 |
| AVIR | 4.3100 | 2.13% | 345682253 |
| CCAP | 9.3800 | -0.74% | 345615480 |
| OBIO | 5.6800 | 1.07% | 341396678 |
| OFIX | 7.8700 | -11.77% | 318118401 |
| ZIP | 3.7600 | 1.08% | 309172324 |
| URG | 0.7431 | 7.12% | 295652515 |
| RNGR | 12.5200 | -1.11% | 292993040 |
| OPI | 12.9900 | 0.78% | 285176965 |
| PPHC | 11.1700 | -1.50% | 281272552 |
| AMCX | 8.3900 | -0.47% | 272199287 |
| EVI | 20.8300 | -1.51% | 270189700 |
| BETRW | 0.1314 | 4.95% | 269085281 |
| BETR | 19.2400 | 1.42% | 255046152 |
| LTRX | 5.1650 | 3.30% | 242132101 |
| CNCK | 1.2600 | -0.79% | 241315504 |
| ABEO | 4.1700 | 6.65% | 238457280 |
| INR | 12.7900 | 4.41% | 238431551 |
| OSUR | 3.4400 | 2.08% | 237251984 |
| IHRT | 1.7700 | -5.35% | 236647230 |
| FF | 5.3200 | -1.48% | 233352852 |
| KLTR | 1.5200 | 2.70% | 231877520 |
| SVCC | 10.7000 | -4.55% | 231279676 |
| AIV | 1.5500 | -1.90% | 225117192 |
| OSG | 4.9900 | -2.92% | 224806915 |
| SNFCA | 9.4800 | 1.39% | 223616136 |
| TROO | 1.8300 | 5.17% | 223552800 |
| SIGA | 3.1000 | 4.38% | 222734070 |
| IMXI | 7.3400 | 0.55% | 221753144 |
| SGC | 13.4400 | 0.98% | 214303488 |
| MVST | 0.6287 | 9.47% | 209455806 |
| SCM | 7.2700 | 0.69% | 207049142 |
| ALTG-PA | 25.2469 | -0.76% | 202210047 |
| ADCT | 1.5800 | -3.66% | 201714958 |
| MPAA | 10.5200 | 3.59% | 199177264 |
| PALI | 1.1300 | -2.59% | 196925731 |
| BKKT | 4.3000 | 3.12% | 193798669 |
| ALTG | 5.9300 | 2.60% | 193714551 |
| ABAT | 1.3350 | 11.72% | 190341307 |
| CGEN | 1.9600 | 2.08% | 185659326 |
| WHF | 8.3900 | 1.82% | 180187835 |
| WHFCL | 25.2500 | 0.13% | 180187813 |
| JRVR | 3.8900 | -2.75% | 179908610 |
| MRT | 2.0700 | 6.15% | 178108389 |
| AMRO | 5.4500 | 1.87% | 155537893 |
| ANTX | 4.0000 | 1.14% | 150944948 |
| LDI | 0.6399 | 2.30% | 148602430 |
| LFMDP | 21.2800 | -0.09% | 145104894 |
| DOUG | 1.5600 | -0.64% | 141789138 |
| RAIL | 4.2400 | 2.17% | 139035027 |
| AMPY | 3.3300 | 4.72% | 138049979 |
| QTRX | 2.8950 | 4.89% | 136913423 |
| SPRB | 46.5500 | 8.99% | 133785165 |
| EXOD | 4.0700 | 3.83% | 122927260 |
| TMCR | 1.8000 | 1.12% | 121345240 |
| CHRS | 0.7700 | 2.82% | 118965744 |
| LFMD | 2.3700 | 3.49% | 114366334 |
| FHTX | 1.8700 | -1.84% | 111050511 |
| GHI | 4.4300 | 0.00% | 104381919 |
| GAING | 25.0550 | 0.26% | 100220000 |
| BDTX | 1.7350 | 4.52% | 99418578 |
| CATX | 0.8400 | 6.54% | 95887397 |
| CBAT | 1.0450 | 2.45% | 92634861 |
| FDSB | 17.6900 | 0.11% | 92618790 |
| ISPR | 1.5500 | 8.39% | 89519429 |
| TNXP | 4.7400 | 3.04% | 81295740 |
| HFFG | 1.4700 | 2.08% | 79234323 |
| NRXS | 6.2400 | 2.13% | 78360454 |
| TTEC | 1.3800 | -6.76% | 68028342 |
| LFVN | 5.2200 | 3.37% | 65716898 |
| HYPR | 0.7195 | 4.98% | 65469738 |
| DGNX | 1.1800 | 2.61% | 59153553 |
| HRTX | 0.2930 | 4.64% | 55626726 |
| AREN | 1.1200 | 19.15% | 53315125 |
| NRDY | 6.2300 | 5.77% | 52955000 |
| VOC | 2.9500 | 0.34% | 50150000 |
| HDRN | 0.6863 | 1.67% | 49069654 |
| MYPS | 4.6800 | 0.00% | 48514569 |
| MYO | 1.2100 | 1.68% | 47925503 |
| MREO | 0.2830 | 0.93% | 45192545 |
| FJET | 0.8181 | 9.75% | 44992242 |
| OPAL | 1.4500 | 5.84% | 43921896 |
| PAAI | 0.8936 | 7.66% | 42544922 |
| WPRT | 2.2200 | -0.89% | 42170454 |
| ANTA | 1.6200 | -1.52% | 38867876 |
| LPSN | 3.1000 | 0.00% | 38245621 |
| VRM | 6.5300 | -2.10% | 34180345 |
| AVD | 0.9627 | 1.55% | 28400228 |
| DCGO | 0.2450 | 0.57% | 24253125 |
| SEAT | 2.0900 | -23.72% | 23494098 |
| CRVO | 1.4200 | -2.07% | 21469116 |
| CKX | 10.3700 | -0.77% | 21290948 |
| JSPR | 16.8600 | 19.78% | 18700303 |
| NCT | 1.0399 | -28.28% | 16656609 |
| KYNB | 3.7300 | 1.91% | 15103218 |
| PIIIW | 0.0069 | 16.95% | 13883653 |
| HAIN | 0.1494 | 10.01% | 13595739 |
| AIRI | 2.8000 | 5.26% | 13581848 |
| PIII | 4.0000 | 4.71% | 13104004 |
| PASG | 3.9750 | 14.88% | 12790795 |
| BBGI | 5.9000 | 5.73% | 12111231 |
| TULP | 2.3400 | -0.64% | 11304458 |
| GETY | 0.0200 | 29.03% | 8296226 |
| OXBR | 0.8741 | 13.52% | 7113930 |
| OXBRW | 0.1600 | 22.14% | 6266704 |
| PRSO | 0.3510 | 0.21% | 5287640 |
| GDC | 1.2000 | 9.09% | 4995000 |
| AQMS | 1.2550 | 7.26% | 4472230 |
| SKYE | 0.9903 | -4.78% | 4384728 |
| ADXN | 2.9000 | 0.00% | 3572603 |
| CVKD | 0.9800 | -2.00% | 3496240 |
| HDRNW | 0.0501 | -28.53% | 1670000 |
| FXHO | 5.0900 | -14.31% | 1004700 |
| SHFS | 0.0263 | -1.13% | 324357 |
| MPU | 1.2900 | -3.73% | 147444 |
6-K/8-K Form Update
WHWK
Whitehawk Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2026, with cash, cash equivalents, and short-term investments totaling $169.7 million, expected to fund operations until mid-2028. The company announced the initiation of a Phase 1 trial for HWK-206 in the U.S., which received Fast Track designation from the FDA, and submitted an IND application in China, planning to activate clinical sites in Q1 2027. Whitehawk also highlighted ongoing Phase 1 trials for HWK-007 and HWK-016, with initial data expected by year-end 2027, and presented analyses supporting PTK7 and MUC16 as ADC targets in cancer. Research and development expenses rose to $18.1 million for Q3 2026, up from $14.3 million in Q3 2025, with a net loss of $21.2 million, compared to $17.7 million in the prior year's Q3.
DCTH
Delcath Systems, Inc. reported a 70% increase in third-quarter 2026 revenue to $35.1 million, driven by HEPZATO KIT sales of $32.7 million and CHEMOSAT revenue of $2.4 million. The company achieved a gross margin of 89% and net income of $7.0 million, with non-GAAP adjusted EBITDA rising to $11.5 million. Delcath anticipates fiscal year 2026 revenue between $115 million and $117 million, reflecting a minimum 41% increase in HEPZATO KIT volume over 2025.
CNH
CNH Industrial N.V. and CNH Industrial America LLC have agreed to sell a 70% interest in their Construction Equipment business to Kobelco Construction Machinery Co., Ltd., Kobelco Construction Machinery Investment U.S.A. LLC, and Kobe Steel, Ltd. The transaction, valued at $700 million in cash, involves the formation of new UK and Delaware entities and is expected to close by the end of 2027, pending regulatory approvals. CNH Industrial will retain a 30% interest in the business and will also sell its Indian construction equipment subsidiary to CE JV.
CMPX
Compass Therapeutics, Inc. reported third-quarter 2026 financial results, revealing a net loss of $27.2 million or $0.15 per share, compared to $14.3 million or $0.08 per share in the same period of 2025. The company's cash and marketable securities decreased to $163 million as of September 30, 2026, primarily due to $48 million used in operating activities, with an anticipated cash runway extending into 2028. Compass is advancing preparations for a Biologics License Application (BLA) submission for tovecimig, a DLL4 x VEGF-A bispecific antibody, in patients with biliary tract cancer, demonstrating statistically significant improvements in overall response rate and progression-free survival compared to paclitaxel alone.
SIRI
Sirius XM Holdings Inc. appointed Anjali Sud as its new Chief Executive Officer, effective January 1, 2027, succeeding Jennifer C. Witz. Sud, previously CEO of Tubi, Inc., and Vimeo, Inc., brings extensive experience from her tenure at Amazon.com, Inc. The employment agreement includes a base salary of $2.6 million, potential bonuses up to twice her salary, and stock incentives under the 2024 Long-Term Stock Incentive Plan, with an initial term through December 31, 2029.
CDTTW
CDT Equity Inc. received a non-binding proposal from Corvus Capital Limited and Manoira Limited, through their shareholder Dr. Andrew Regan, to acquire all outstanding common stock at $2.00 per share, a 96.3% premium to the closing price on November 4, 2026. The Board plans to establish a special committee of independent directors to evaluate, negotiate, and decide on the proposal and any other strategic alternatives. The committee has not yet received definitive terms and is not obligated to provide updates beyond legal requirements.
CECO
CECO Environmental Corp. reported a robust third quarter 2026 performance, with orders surging 234% to $777.6 million and backlog increasing 205% to $2,193.5 million. Revenue climbed 105% to $404.4 million, while gross profit rose 101% to $130.1 million. Adjusted EBITDA jumped 202% to $70.1 million, and free cash flow improved by $137.3 million to $148.4 million. The company raised its 2026 full-year orders outlook to exceed $2.5 billion, with revenue projected between $1.300 billion and $1.375 billion, and Adjusted EBITDA between $200 million and $225 million. For 2027, CECO anticipates revenue between $2.1 billion and $2.3 billion, Adjusted EBITDA between $475 million and $525 million, and free cash flow between 50% and 60% of Adjusted EBITDA.
AIRI
Air Industries Group reported significantly improved financial results for the three and nine months ended September 30, 2026. For the three months, net sales increased by 41.1% to $14.6 million, with operating income surging by 311% to $1.3 million. Excluding merger-related costs and non-cash stock compensation, pro-forma operating income reached $1.838 million, a 293% increase. For the nine months, net sales grew by 8.7% to $38.2 million, and pro-forma operating income reached $2.9 million, a 950% increase.
BPOPM
Popular, Inc. recognized a subsequent event requiring adjustment of its interim consolidated financial statements for the quarter ended September 30, 2026, following a borrower's bankruptcy filing. The company recorded an additional provision for credit losses of $38 million, increasing the allowance for credit losses to loans held-in portfolio, net, to $808.8 million. This adjustment decreased total loans held-in portfolio, net, to $39.23 billion, reflecting the financial impact of the borrower's cessation of operations.
VRDN
Viridian Therapeutics, Inc. announced positive phase 1 results for VRDN-008, a half-life extended bispecific FcRn inhibitor, demonstrating a 74% reduction in immunoglobulin G (IgG) levels with an extended half-life of 15-18 days. The trial results support a transformative every-eight-week dosing profile, with plans to initiate a pivotal clinical trial for myasthenia gravis in mid-2027, pending regulatory feedback. Viridian aims to advance VRDN-008's clinical development and may explore opportunities for VRDN-006 in the future.
ANTX
AN2 Therapeutics, Inc. reported third-quarter financial results for the period ended September 30, 2026, highlighting key developments. The company announced the clearance of its Phase 2 global study of oral epetraborole in polycythemia vera, with enrollment expected to commence by year-end. Additionally, AN2 is advancing enrollment in a Phase 2 trial of epetraborole for M. abscessus lung disease and selected AN2-504661 as a development candidate for hypophosphatasia, planning a Phase 1 study in the second half of 2027. The company extended funding for tuberculosis research collaboration with GSK and appointed Eric Easom as Chief Medical Officer in August 2026.
SLNHP
Soluna Holdings, Inc. announced it will release its third quarter 2026 financial results on Monday, November 16, 2026, and host a conference call and webcast beginning at 5:00 PM ET. The company, a developer of green data centers for AI and Bitcoin mining, aims to transform surplus renewable energy into global computing resources through its strategically co-located data centers. Utilizing its proprietary software MaestroOS™, Soluna seeks to energize a greener grid while delivering sustainable computing solutions and superior returns.
AVIR
Atea Pharmaceuticals, Inc. secured compliance by entering into a Loan and Security Agreement with Hercules Capital, Inc. as agent, arranging for senior secured term loans totaling up to $200 million, maturing on November 1, 2031. The agreement includes five tranches, with Tranche 2 contingent on the successful completion of a Phase 3 clinical trial for bemnifosbuvir and ruzasvir, while Tranches 3 and 4 depend on specific development and commercialization milestones.
TNXP
Tonix Pharmaceuticals reported third-quarter 2026 financial results, with TONMYA net sales of approximately $15 million, up 37% from the previous quarter. The company ended September with $163 million in cash and cash equivalents. TONMYA, approved for fibromyalgia treatment, achieved coverage for about 166 million lives. Tonix Pharmaceuticals advanced its clinical programs, including TNX-102 SL, TNX-4800, and TNX-1500, and expanded its sales force by 50 representatives. The company also completed major managed Medicare agreements, adding 30 million lives. Tonix Pharmaceuticals faces a generic drug patent challenge from Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc., regarding TONMYA.
FTH
Faeth Therapeutics, Inc. announced positive preliminary Phase 2 results for PIKTOR in combination with paclitaxel for advanced endometrial cancer with PI3K/AKT/mTOR pathway mutations. The trial showed a confirmed objective response rate of 33% and a disease control rate of 83%, with a 44% response rate among patients with a PIK3CA mutation. The combination was generally well tolerated, supporting advancement into a Phase 3 registrational trial.
ROIV
Roivant reported financial results for the second quarter ended September 30, 2026, with LISRAYA generating $31.0 million in net product revenue in its first five weeks post-FDA approval. IMVT-1402 achieved a primary endpoint of ACR20 response at Week 28 in a trial for difficult-to-treat rheumatoid arthritis, while brepocitinib met all key endpoints in Phase 3 trials for non-infectious uveitis, with a sNDA submission expected in early 2027. Mosliciguat showed positive data in a Phase 2 study for pulmonary hypertension associated with interstitial lung disease, and the Phase 3 study has commenced. Roivant's consolidated cash, cash equivalents, and marketable securities stood at $4.2 billion as of September 30, 2026, bolstered by a cash payment from Moderna, supporting its path to profitability.
TNGX
Tango Therapeutics, Inc. reported promising Phase 1/2 data for its combination study of vopimetostat plus daraxonrasib in metastatic pancreatic cancer, achieving an 82% objective response rate and 88% nine-month progression-free survival. The company plans to initiate a pivotal Phase 3 study in the first half of 2027 for front-line MTAP-deleted pancreatic cancer. As of September 30, 2026, Tango's cash position stood at $977.5 million, with collaboration revenue dropping to $0 due to the end of the Gilead agreement, and R&D expenses rising to $48.9 million.
SGC
Superior Group of Companies, Inc. reported third-quarter 2026 results with net sales of $146.0 million, up 5% from the prior year. Net income was $2.6 million or $0.17 per diluted share, compared to $2.7 million or $0.18 per diluted share in the same period of 2025. The company tightened its full-year net sales forecast to $578.0 million to $585.0 million and adjusted EPS forecast to $0.60 to $0.66, representing 43% growth at the high end. Additionally, Superior announced the acquisition of Select VoiceCom and a return of capital to shareholders.
IMVT
Immunovant (IMVT) reported second fiscal quarter results ending September 30, 2026, with cash and cash equivalents at $722.3 million, supporting its commercial launch plans for IMVT-1402 in Graves' disease. The company achieved a primary endpoint of ACR20 response at Week 28 in a trial for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with 92.5% of participants responding compared to 75.6% in the placebo group (p<0.0139). Research and development expenses decreased to $85.0 million from $114.2 million in the prior year.
AURA
Aura Biosciences, Inc. announced the completion of enrollment in its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma, with all participants now in the 24-month follow-up period. The trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027, aiming to establish bel-sar as a potential vision-preserving therapy. Additionally, Aura Biosciences has partnered with a leading Contract Development and Manufacturing Organization (CDMO) and expects a cash runway into the first half of 2029.
EDIT
Editas Medicine, Inc. announced its third quarter 2026 financial results and secured approval from Australia's Therapeutic Goods Administration (TGA) to initiate the Phase 1/2 Strive study of EDIT-401 for Heterozygous Familial Hypercholesterolemia (HeFH). The company reported a cash runway extending into the second half of 2028, with enrollment for Part 1 of the Strive study expected to complete by mid-2027, and topline safety and efficacy results anticipated thereafter. New preclinical data presented at the AHA Scientific Sessions 2026 showed durable LDL-C lowering with EDIT-401 maintained over 10 months in non-human primates.
PRAX
Praxis Precision Medicines, Inc. reported third-quarter financial results for 2026, revealing a cash and investments balance of approximately $1.3 billion as of September 30, 2026, with a runway extending into 2028. The company experienced a net loss of $94.2 million, driven by increased research and development expenses of $64.2 million and general and administrative expenses of $42.7 million. Praxis is advancing its CNS precision neuroscience programs, with ongoing FDA reviews for relutrigine and ulixacaltamide HCI, and has initiated a strategic collaboration with Remagine Labs for ulixacaltamide.
PROK
ProKidney Corp. reported cash and cash equivalents of $141.9 million as of September 30, 2026, supporting its operations into mid-2027. The company updated its investor presentation, highlighting the anticipated topline data from the PROACT 1 trial in Q2 2027 and potential regulatory approval for its Phase 3 REGEN-006 program, targeting kidney function stabilization in advanced CKD and type 2 diabetes patients. ProKidney faces risks related to Nasdaq compliance, regulatory approvals, and the need for additional financing.
IONS
Ionis Pharmaceuticals, Inc. reported a 55% year-over-year revenue increase in the third quarter of 2026, driven by commercial and R&D revenue from partnerships. The company adjusted its TRYNGOLZA sales guidance due to a slower-than-expected launch, while reaffirming its total revenue, operating loss, and cash guidance for 2026. Ionis highlighted progress on key programs, including FDA-approved TRYNGOLZA for severe hypertriglyceridemia, DAWNZERA for hereditary angioedema, and ZANVASTRO for Alexander disease, with further potential approvals and revenue growth opportunities.
TTRX
Turn Therapeutics Inc. reported its financial and operating results for the quarter ended September 30, 2026, showcasing promising clinical trial outcomes. The company completed a GX-03 Stage 1/Phase 2a trial, with 59.3% of patients achieving clear or almost clear skin after four weeks, compared to 30.4% receiving a vehicle. Additionally, 40.7% of patients reached EASI-100 at Week 8, versus 17.4% on the vehicle. The ongoing Phase 2b trial for atopic dermatitis continues with no patient dropouts and a dropout rate below 5%. Turn Therapeutics also accelerated patient enrollment for a Phase 2a trial of GX-03 for hidradenitis suppurativa, expected to start in Q1 2027. The company anticipates sufficient cash to fund operations through Q3 2027, with additional capital available from existing facilities. Former CDC Director Robert R. Redfield, M.D., was appointed Chief Scientific Officer on September 9, 2026.
KKRS
KKR & Co. Inc. reported record Fee Related Earnings, Total Operating Earnings, and Adjusted Net Income per share for the third quarter of 2026, with a commitment to return over $40 billion to clients, surpassing the previous annual record by more than 50%. The company announced a conference call on November 9, 2026, to discuss its financial results, which are detailed in an earnings release for the quarter and nine months ended September 30, 2026.
ABEO
Abeona Therapeutics reported a third-quarter 2026 net revenue of $13.5 million from ZEVASKYN, marking an 18% increase from Q2 2026, driven by 15 patient treatments. The company expanded its ZEVASKYN Qualified Treatment Center network to eight sites and acquired APT-1011, a Phase 3-ready oral disintegrating tablet for eosinophilic esophagitis, in a $30 million PIPE financing. Additionally, Abeona acquired ABO-801, another Phase 3-ready formulation for EoE, from Ellodi Pharmaceuticals, with potential milestone payments upon FDA approval and sales achievements.
SEATW
Vivid Seats Inc. announced a recapitalization agreement in principle with a majority of its term loan lenders, securing $60 million in new term loans, converting a significant portion of existing debt into equity, reducing funded debt by approximately $200 million, and extending the maturity on remaining debt. The company reported third-quarter 2026 results with a Marketplace Gross Order Value of $624.0 million, revenues of $126.9 million, a net loss of $17.4 million, and an Adjusted EBITDA of $8.9 million, marking a return to year-over-year growth in GOV and Adjusted EBITDA.
KGS
Kodiak Gas Services, Inc. reported record third-quarter 2026 revenues of $318.4 million in its Compression Infrastructure segment, a 7.2% increase from the previous year, with an adjusted gross margin of 70.0%, up 9.9%. The Power Infrastructure segment saw revenues rise 27.6% to $42.0 million, with a 75.2% adjusted gross margin, while the Other Services segment experienced a 60.6% revenue increase to $41.4 million, with an 11.3% adjusted gross margin. The company raised its full-year 2026 Adjusted EBITDA guidance to $840 million-$860 million and discretionary cash flow to $580 million-$600 million, announced a dividend increase to $0.51 per share, and extended its share repurchase program to December 31, 2027, with $31.7 million available.
CKX
CKX Lands, Inc. secured a $1 billion equity investment from Jacobs Private Equity II, LLC, with Jacobs Private Equity becoming the controlling stockholder. Following the investment's closing, Mr. Brad Jacobs will assume the roles of chairman and CEO. The agreement is contingent on closing conditions and regulatory approvals, and failure to complete the transaction could materially impact CKX Lands' business prospects and stock price.
CNTN
Canton Strategic Holdings, Inc. executed the first trades of its tokenized common stock on TSV LLC, under the SEC's Innovation Exemption for Onshore U.S. Equities. The trades, involving Five North, DRW Cumberland, and Flowdesk Liquidity Solutions LLC, marked the first transactions in tokenized Nasdaq-listed stock under this exemption. Fairmint, the SEC-registered transfer agent, recorded the shares in token form, maintaining the official onchain record of ownership on the Canton Network, ensuring institutional market readiness and shareholder rights.
BRK-A
Berkshire Hathaway Inc. reported third-quarter and nine-month earnings for 2026, with net earnings attributable to shareholders at $22.1 billion and $57.9 billion, respectively, compared to $30.8 billion and $47.8 billion for the same periods in 2025. The company also announced the acquisition of approximately $9.6 billion in treasury shares during the third quarter and an increase in insurance float to about $178.5 billion as of September 30, 2026.
AITX
Artificial Intelligence Technology Solutions, Inc. (AITX) unveiled RAIA, a portable solar-powered security tower developed by its subsidiary, Robotic Assistance Devices, Inc. (RAD). The device, deployable in about 15 minutes without additional equipment, is designed to capture a 360-degree view with human and vehicle detection, targeting the $1.5 billion global mobile surveillance tower market by 2026. Deliveries are anticipated by the end of Q1 2027, positioning RAD to capture a larger market share with its cost-effective solution.
EDSA
Edesa Biotech, Inc. has entered into an exclusive collaboration and license agreement with KYORIN Pharmaceutical Co., Ltd. for the development and commercialization of paridiprubart, an anti-TLR4 monoclonal antibody, in Japan. The deal is valued at over $140 million, including upfront payments and potential milestones, with Edesa receiving $12 million upfront and eligible for up to $134 million in additional payments, plus double-digit royalties on net sales. Kyorin will fund development and commercialization in Japan, with rights to negotiate for additional indications.
CDLR
Cadeler A/S is initiating a compulsory acquisition of remaining minority shares in accordance with Danish law, following a voluntary share exchange offer. Cadeler plc, holding over 90% of Cadeler A/S shares, will acquire the remaining shares at a Redemption Price of NOK 58.42 per share, based on the volume-weighted average price over the preceding 30 trading days. Shareholders are requested to transfer their shares by 7 December 2026, concluding the Compulsory Acquisition Period.
CANF
Can-Fite BioPharma Ltd. announced a significant milestone in its clinical development of Namodenoson, a drug targeting advanced liver cancer. A patient from its completed Phase II study reached a ten-year overall survival, extending the previously reported nine-year survival. Namodenoson is currently under evaluation in a Phase III study, with overall survival exceeding initial expectations.
MCTA
Charming Medical Limited faces imminent delisting from Nasdaq due to non-compliance with Listing Rule IM-5101-4, resulting in the suspension of trading on November 9, 2026. The U.S. Securities and Exchange Commission had previously suspended trading from November 12-25, 2025, amid concerns of potential manipulation via social media. Nasdaq will file a Form 25-NSE with the SEC to remove the company's securities from listing, though this delisting does not immediately affect ongoing business operations.
KSPI
Kaspi.kz reported unaudited consolidated IFRS financial results for the quarter and nine months ended September 2026, showing an 18% year-over-year increase in consolidated revenue to KZT1.1 trillion ($2.5 billion) on a constant-currency basis. Adjusted EBITDA rose 1% to KZT408 billion ($925 million), while net income reached KZT281 billion ($637 million). The company's e-Commerce business saw a 27% increase in annualized purchases per consumer, with e-Commerce revenue growing 23% to KZT343 billion ($779 million). Kaspi.kz also announced a proposed quarterly dividend of KZT1,000 per ADS, subject to shareholder approval, and highlighted its expansion into Kazakhstan's $9 billion neighbourhood grocery market through Magnum Daily stores.
SID
Companhia Siderúrgica Nacional (CSN) agreed to sell shares of CSN Cimentos Brasil S.A. to Huaxin Building Materials Group Co. for an enterprise value of R$ 12.7 billion. The transaction, subject to regulatory approvals, aims to reduce CSN's indebtedness and balance its capital structure. Completion is expected once conditions, including approvals from Brazil's Administrative Council for Economic Defense and China's regulatory bodies, are met.
MRT
Marti Technologies, Inc. reported record third-quarter results ending September 30, 2026, with revenue surging 128.1% year-over-year to $24.7 million, driven by robust platform monetization. The company achieved positive operating income for the first time at $2.7 million, compared to a loss of $8.8 million in Q3 2025. Gross profit rose 176.0% year-over-year to $20.2 million, with the gross profit margin expanding significantly to 81.5%.
TUYA
Tuya Inc. will report its third quarter 2026 unaudited financial results after the market closes on November 23, 2026. The company's management will hold a conference call at 07:30 P.M. Eastern Time on the same day to discuss the results. Participants must register online to receive dial-in information and a unique PIN, with a live and archived webcast available on Tuya's investor relations website.
ARGX
Argenx SE agreed to acquire Unnatural Products, Inc. (UNP) for up to approximately $1.15 billion, enhancing its immunology innovation capabilities with a macrocyclic peptide discovery engine. The deal, expected to close by year-end, includes a $550 million upfront payment and up to $595 million in contingent payments based on development and regulatory milestones. Following the acquisition, UNP's team will operate from Santa Cruz, California, while argenx advances UNP's medicines with its clinical and commercialization expertise.
Pre-Market Options Data
